Lonza Group AG (LONNN.MX)
| Previous close | 9,877.51 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 9,175.72 - 9,175.72 |
| 52-week range | 6,443.40 - 9,991.55 |
| Volume | |
| Avg. volume | 2,432 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | 12.03 |
| EPS (TTM) | 828.29 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireNeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
- Reuters
UPDATE 2-Luxury stocks pressure European equities ahead of Fed verdict
European shares were flat on Wednesday, pressured by a sell-off in luxury stocks and in the absence of big bets by investors ahead of a crucial Federal Reserve meeting later in the day. The pan-European STOXX 600 index ended largely unchanged at 505.34 points, with the personal and household goods index housing luxury stocks, down 1.3% and leading declines.
- Reuters
UPDATE 3-Lonza to buy large biologics site from Roche in US for $1.2 bln
Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion. Lonza plans to spend another 500 million Swiss francs ($562.3 million) to upgrade the facility in Vacaville, which makes monoclonal antibodies from genetically modified living cells, to produce a new generation of drugs, the company said in a statement. Roche unveiled plans to sell the site in May last year, saying it no longer needs the very large antibody volumes the plant provides, as it plans to focus on drugs targeting smaller patient populations and a range of biotechnology methods beyond monoclonal antibodies.
